



Numelvi®

The Future of Itch Relief

The first and only second generation JAK inhibitor for dogs



Rapidly effective

- Significant reduction in itch 2 hours after first dose
- For the treatment of pruritus associated with allergic dermatitis including atopic dermatitis in dogs
- For the treatment of inflammation and clinical manifestations of atopic dermatitis in dogs



Proven safety and efficacy

- At least 10X more selective⁺ for JAK1, the primary driver of itch and inflammation
- High selectivity for JAK 1 minimises interference with beneficial functions of other JAKs
- Allows adequate response to vaccination when dosed at 3X maximum recommended dose
- Well tolerated in dogs from 6 months of age



Simple and convenient

- Once daily dosing from day 1
- Broadest age and weight range – the only JAK inhibitor for use in dogs from 6 months of age

⁺Over the other JAK enzymes in *in vitro* assays.



NUMELVI is the only JAK inhibitor for dogs that is highly selective

High selectivity for JAK1 leads to a favourable therapeutic index

The importance of selectivity

- Cytokines use Janus kinase (JAK) enzymes to stimulate immune cells
- JAK1 is the primary driver of itch and inflammation
- First-generation JAK inhibitors target the JAKs with little to no selectivity
- High selectivity for JAK1 reduces itch and inflammation associated with allergic and atopic dermatitis, and minimises interference with the beneficial functions of other JAKs such as haematopoiesis and immune function.



At least 10X more selective for JAK1

Over the other JAK enzymes in *in vitro* assays.



Scan to visit numelvivets.nz, our vet only website.

Most dogs require 1 whole or half-tablet daily*

Body weight of dog	Strength and number of Numelvi tablets to be administered			
kg	4.8 mg SMALL	7.2 mg MEDIUM	21.6 mg LARGE	31.6 mg EXTRA LARGE
2.0 – 2.9**	½			
3.0 – 4.3		½		
4.4 – 6.0	1			
6.1 – 9.0		1		
9.1 – 13.5			½	
13.6 – 19.3				½
19.4 – 26.5			1	
26.6 – 39.5				1
39.6 – 54.0				1 ½
54.1 – 79.0				2

½ or 1 tablet once daily

Numelvi should not be used in dogs less than 6 months of age.

*Administer with food. Dogs weighing more than 79.0 kg can be dosed with the appropriate number of full or half tablets to achieve a target dose of 0.8 – 1.2 mg/kg body weight.

**A benefit-risk assessment should be made by the responsible veterinarian for dogs less than 3 kg as safety has not been investigated in these dogs.

Please refer to the registered product label for full claim information.

Itch relief is simple with Numelvi

Numelvi is an ideal first-line treatment

At least 10X more selective⁺ for JAK1^{1,2,3}

For dogs and puppies from 6 months of age

Tablet strengths for dogs as small as 2 kg** in weight

Once-daily dosing from day 1

36 month shelf life

	Numelvi (atinvicitinib) ¹	Oclacitinib ²
At least 10X more selective ⁺ for JAK1 ^{1,2,3}	✓	✗
For dogs and puppies from 6 months of age	✓	✗
Tablet strengths for dogs as small as 2 kg** in weight	✓	✗
Once-daily dosing from day 1	✓	✗
36 month shelf life	✓	✗

Experience selectivity, safety and simplicity in the management of canine allergic dermatitis. To learn more, contact your MSD Animal Health Territory Manager or call 0800 800 543.



References:

1. European Medicines Agency. Numelvi: PUAR – Product Information. 2025.
2. European Medicines Agency. Apoquel: PUAR – Product Information & Assessment Report. 2025.
3. Gonzales AJ, Bowman JW, Fici GJ, et al. *J Vet Pharmacol Ther.* 2014;37(4):317-324.

Numelvi is AVAILABLE ONLY UNDER VETERINARY AUTHORISATION. ACVM No: A012149.
Schering-Plough Animal Health Ltd. Ph: 0800 800 543. www.msd-animal-health.co.nz.
NZ-NUM-250600001. © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.